Company profile

HKND YB1 PHARMACEUTUCAL LIMITED. focuses on the research and development of innovative drugs in the field of tumor targeted treatment. It has the world's leading platform for the oncolytic bacteria based on synthetic biology, providing revolutionary cancer immunotherapy solutions.

In 2011, Inventor Dr. Yu Bin from the University of Hong Kong and his team, first realized the high efficiency programming technology of Salmonella Lambda-RED in the research, and established the basis for the biological transformation of Salmonella synthesis. After more than 10 years of development cycle, Dr. Yu Bin and his R & D team successfully invented a cancer immunotherapy technology for oncolytic bacteria, and named the Salmonella typhimurium ‘YB1’ which is genetically programmed.

YB1, the first oncolytic bacterial therapy in the world, is highly safe and effective, and has extensive expansibility. Because of its super carrying capacity, YB1 can be used as a super oncolytic delivery carrier. It can carry a variety of warheads for different tumors, and combine with a variety of therapeutic antibodies, toxins, oncolytic bacteria and drugs to become a super oncolytic weapon. It can accurately target the hypoxia region of the tumor center, inhibit its growth without damaging normal tissues and organs, and inhibit tumor metastasis, It has great clinical application potential.

In 2012, the founder team completed the application for invention patents related to YB1. In the same year, the first paper of YB1 was published in a sub Journal of the famous academic journal Nature; in 2013, the invention patents related to YB1 were authorized in the United States, the European Union and China.

In 2016, Noopy, the first pet dog with malignant sarcoma, was cured after YB1 treatment. By 2020, the clinical study on PET cancer YB1 had been completed, and more than 100 pet dogs with cancer had been enrolled; and Noopy had also achieved 4-year cancer-free survival.

In 2021, HKND YB1 PHARMACEUTUCAL LIMITED. established a strategic partnership with HKU and obtained exclusive authorization and ommercial exploitation rights of all YB1 patents.

In the future, HKND YB1 PHARMACEUTUCAL LIMITED. will continue to explore in the field of tumor targeted therapy, accelerate the human clinical trial research of YB1 oncolytic bacterial therapy, expand different tumor treatment pipelines and actively push forward the commercialization. Trying to contribute to the research and development of innovative drugs for human anti-cancer and tumor treatment.


  • 2011
    For the first time, the high efficiency programming technology of Salmonella Lambda-RED was realized, and the foundation of synthetic biology transformation of Salmonella was established.
  • 2012
    Apply for YB1 related invention patents, including PCT, the United States, the European Union, China, etc;
    The first paper of YB1 was published in the subsidiary of the famous academic journal Nature.
  • 2013
    YB1 related patents of the United States, EU and China are authorized;
  • 2016
    It was the first time that the pet dog named Noopy with malignant sarcoma was recovered by using YB1.
  • 2020
    Completed the pet cancer YB1 clinical study, involving over 100 pet dogs with cancer. The Pet dog Noopy achieved 4-year cancer-free survival;
  • 2021
    HKND YB1 PHARMACEUTICAL LIMITED has established a strategic partnership with HKU of the University of Hong Kong and obtained the exclusive license and commercial exploitation right of all YB1 patents;
  • 2021
    On May 5, 2021, Inventor Dr. Yu Bin from the University of Hong Kong and his team published the title "IFN" in the international well-known journal Nature Communications- γ- The research paper of dependent NK cell activation is essential to metastasis suppression by engineered Salmonella, elaborates the principle of YB1, a tumor solubilizing bacteria invented by Dr. Yu Bin team, and provides an important research direction for cancer immunotherapy. The influence factors of the paper are more than 20;

Team Introduction

Dr. Yu BinInventor



2007.11-2012.12 The University of Hong Kong

Department of Biochemistry | PhD in Biochemistry

Under the tutelage of Hong Kong SARS academician Prof Kwok-Yung YUEN and synthetic

biology pioneer in China Professor Jiandong HUANG. Research topics include the

identification of various pathogenic microorganisms such as Salmonella and avian

influenza through high-throughput NGS sequencing technology. Application of

Lambda-RED-based homologous recombination system in Salmonella typhimurium and

other pathogenic microorganisms; development of genetic engineering vaccines for H5N1

and H7N9 avian influenza; development of transgenic chickens with high expression of IgY

antibody against avian influenza HA; oncolytic vector Salmonella YB1 The development of

oncolytic vectors; the research on the presentation of single-chain fragment antibody ScFv.

During the doctoral dissertation period, obtained two US patents, one EU patent in 30

countries, one Chinese patent, and published more than ten high-quality English SCI

academic papers.


2009.1-2009.12, went to the Massachusetts Institute of Technology (MIT) exchange for

participating in the International Synthetic Biology Competition and served as the team

leader instructor of the University of Hong Kong and Hong Kong Baptist University


2004.9-2006.7 SUN YAT-SEN University

Biochemistry and Molecular Biology | Master in Science

During the period I was focused on the medical development of biological macromolecules.

Including thrombolytic human urokinase, genetic engineering and industrial production of human erythropoietin (EPO).


2000.9-2004.7 Shandong University

Life Sciences | Bachelor in Science




Professional certificate in Institut Pasteur France bioinformatics.

Professional certificate in Harvard VPAL CRISPR Gene editing Applications, under the

tutelage of Prof. ALAIN VIEL, Department of Molecular and Cellular Biology, Harvard


Professional certificate in CAR-T cell technology in China.




1999, the first prize of the International Olympic Biology Competition, Shandong

Province, and was recommended for admission to Shandong University

2000, President Scholarship of Shandong University

2009, Gold medal of International Genetically Engineered Machine (iGEM) Competition


2010, The 13th 'REACH UP TO THE STARS' Award ;of The University of Hong Kong

2011, Silver medal (Asia) of International Genetically Engineered Machine (iGEM)

Competition (Adviser)

2016, Represented the Hong Kong University team to participate in the 6th China-US

Health Summit (Top Ten)

2018, the "X-plan" champion of science and technology talents in the

Guangdong-Hong Kong-Macao Greater Bay Area, and the Chief Executive of Hong

Kong Special Administrative Region Carrie Lam presented the award;

2018, the "China Merchants Cup" Qianhai Guangdong, Hong Kong and Macao Youth



1. Publication number: US 9127284 B2

Publication type: Grant

Application number: US 13/871,716

Publication date: Sep 8, 2015

Filing date: Apr 26, 2013

Priority date: May 4, 2012

Also published as: CN104471057A, EP2844736A1, EP2844736A4, US20130295054,


Inventors: Jian-Dong Huang, Bin Yu, Mei Yang, Lei Shi

Invention: Modified Bacteria and their Uses thereof for the Treatment of Cancer


2. Publication number: US 20150064215 A1

Publication type: Application

Application number: US 14/019,058

Publication date: Mar 5, 2015

Filing date: Sep 5, 2013

Priority date: Sep 5, 2013

Also published as: WO2015032165A1

Inventors: Jian-Dong Huang, Lei Shi, Bin Yu

Invention: Therapeutic delivery and expression system, methods and uses thereof- 5 -


3. Publication number: CN 111235638 A

Publication type: Application

Application number: CN202010104572.XA

Inventors: Bin Yu, Miao Jiang

Invention: Method and reagent test kit for constructing sequencing library


4. Publication number: CN 111304306 A

Publication type: Application

Application number: CN202010152358.1A

Inventors: Bin Yu, Miao Jiang

Invention: Method and reagent test kit for constructing sequencing library by fusion primer(A fusion primer NGS sequencing combination for rapid construction and amplification of HIV-resistant pol gene library)


5. Publication number: 2020105585498

Publication type: Application

Application number: 2020105585498

Inventors: Bin Yu, Miao Jiang

Invention: HIV-1 viral load real-time fluorescence quantitative PCR detection specific primer pair, reagent test kit


6. Publication number: 202010149324.7

Publication type: Application

Application number: 202010149324.7

Inventors: Bin Yu, Miao Jiang

Invention: A photochemical inactivation method of coronavirus and vaccine(Photochemical inactivation method of SARS-CoV-2 virus in plasma)




1. Yu B, Yang M, Wong HY, Watt RM, Song E, Zheng BJ, Yuen KY, Huang JD. A

method to generate recombinant Salmonella typhi Ty21a strains expressing

multiple heterologous genes using an improved recombineering strategy. Appl

Microbiol Biotechnol. 2011, 91(1): 177-188


2. Yu B*, Yang M*, Shi L, Yao Y, Jiang Q, Li X, Tang L, Zheng B, Yuen K, Smith D, Song E, Huang JD. Explicit hypoxia targeting with tumor suppression by creating an

"obligate" anaerobic Salmonella Typhimurium strain. * equal contribution. Scientific Reports. 2012, 2:436


3. Yu B*, Zheng S*, Chen M, Zhang K, Hua Y, Watt R, Zheng B, Yuen K, Huang JD.

Comparative immunological evaluation of recombinant Salmonella Typhimurium

strains expressing model antigens as live oral vaccines. * equal contribution. BMC

Immunology 2012, 13:54


4. Yang M, Chen J, Su F, Yu B, Su F, Lin L, Liu Y, Huang JD, Song E. Microvesicles

secreted by macrophages shuttle invasion-potentiating microRNAs into breast

cancer cells. Mol Cancer. 2011, 10: 117


5. Yu B*, Zhang B*, Hua Y*, Lau CC, Cai J, Zheng S, Yam W, Kao RY, Sze K, Zheng BJ,

Yuen KY, Huang JD. Recombinant ESAT-6-like proteins provoke protective immune

responses against invasive Staphylococcus aureus disease in a murine model.

Infect Immun. 2014 Nov 3. pii: IAI.02498-14. * equal contribution


6. Cui J, Jin G, Yu B, Wang Z, Lin R, Huang JD. Stable knockdown of Kif5b in MDCK

cells leads to epithelial-mesenchymal transition. 2015 Jul 17-24;463(1-2):123-9.

doi: 10.1016/j.bbrc.2015.05.045. Epub 2015 May 20.


7. Guo ZL, Yu B, Ning BT, Chan S, Lin QB, Li JC, Huang JD, Chan GC. Genetically

modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy

for neuroblastoma. J Hematol Oncol. 2015 Aug 19;8:99. doi:10.1186/s13045-015-0196-3.


8. Yu B, Shi L, Zhang BJ, Zhang K, Peng X, Niu HB, Qu JL. Obligate anaerobic

Salmonella typhimurium strain YB1 treatment on xenograft tumor in

immunocompetent mouse model. Oncol Lett. 2015 Aug; 10(2): 1069–1074.


9. Shi L, Yu B, Cai CH, Huang W, Zheng BJ, Smith DK, Huang JD. Combined

prokaryotic-eukaryotic delivery and expression of therapeutic factors through a

primed autocatalytic positive-feedback loop. Journal of Controlled Release 2016

Jan 28;222:130-40.


10. Yu B*, Li CX*, , Shi L, Geng W, Lin QB, Ling CC, Yang M, Kevin T.P.,Huang JD, Man

K.An “obligate” anaerobic Salmonella strain YB1 suppresses liver tumor growth

and metastasis in nude mice. Oncol Lett. 2016 Nov:177-183 * equal contribution


11. Shi, L., Yu, B, Cai, CH., Huang JD. Angiogenic inhibitors delivered by the type III

secretion system of tumor-targeting Salmonella typhimurium safely shrink tumors

in mice. AMB Expr (2016) 6: 56. doi:10.1186/s13568-016-0226-8


12. Zhang BZ, Cai J, Yu B. A DNA vaccine targeting TcdA and TcdB induces protective

immunity against Clostridium difficile. BMC Infect Dis. 2016 Oct 22;16(1):596.


13. Yu B*, Ning BT*, , Chan S, Chan Jl, Huang JD, Chan GCF. Treatment of

Neuroblastoma with an Engineered “Obligate” Anaerobic Salmonella

typhimurium Strain YB1. J Cancer 2017; 8(9):1609-1618. doi:10.7150/jca.18776. *

equal contribution


14. Xu C, Zhang BZ, Lin Q, Deng J, Yu B, Arya S, Yuen KY, Huang JD. Live attenuated

Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III

secretion system confer protection against Staphylococcus aureus infection. BMC

Infect Dis. 2018 Apr 25;18(1):195. doi: 10.1186/s12879-018-3104-y.


15. Yu B et al. IFN- γ -dependent NK cell activation is essential to metastasis

suppression by engineered Salmonella. Nature Communications

(reference number: NCOMMS-20-03796-T)(in Revision)

Dr. Shi LeiChief scientist
She graduated from the Biochemistry Department of the University of Hong Kong and is now a postdoctoral researcher at MD Anderson Cancer Center of the University of Texas. In recent years, she has published many high-level papers in international famous journals such as cancer cell, nature communication, oncogene, J of control release, J Clin invest, and has two US patents. she is also responsible for scientific reports, cancer biology and medicine, International Journal of oncology, etc.

Dr. Shi Lei mainly studied tumor synthetic biology during her doctoral program. Based on efficient genetic recombination and genetic engineering of various Salmonella, she developed efficient cross-border gene presentation and expression system to destroy tumor microenvironment for tumor treatment. Based on this work, she published six academic papers and awarded two US patents. 

In the post doctoral stage, as the first author, she published papers one after another, revealing the important functions of SIRT1 and sirt7, members of sirtuin family, which are closely related to aging related diseases, in the occurrence and metastasis of breast cancer stem cells (nature communication, 2017, Oncogene 2018), and for the first time revealed that ythdf3 is an important indicator of brain metastasis of breast cancer, proving that up regulation of ythdf3 expression is necessary for multiple cascade reaction steps of brain metastasis (cancer cell 2020).


2002/09-2006/06,Beijing University Of Chemical Technology,college of Life Sciences,Bachelor
2006/09-2008/06,Tianjin University,School of Chemical Engineering,master
2008/09-2013/11,University of Hong Kong,Li Ka Shing Faculty of Medicine,PhD

Work experience

2014/01-2015/06,Assistant Researcher, Faculty of Medicine, The University of Hong Kong Beijing University Of Chemical Technology
2018/01-present,Postdoc, MD Anderson Cancer Center, University of Texas, USA

Main works

1、B. Yu#, M. Yang#, L. Shi, Y.Y. Yao, Q.Q. Jiang, X.F. Li, L.H. Tang, B.J. Zheng, K.Y. Yuen, D.K. Smith, E.W. Song & J.D. Huang. Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella Typhimurium strain. Scientific Reports. 2012, 2:436. 

2、C.H. Cai, L. Shi, W.S. Liu, H.Y. Leung, K.L. Chan, K.M. Yao & Y.S. Ngan & D.W. Chan. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling. Oncotarget. 2014 Sep; 5(17): 7549–7562. 

3、B. Yu, L. Shi, B.Z. Zhang, K. Zhang, X. Peng, H.B. Niu, J.L. Qu. Obligate anaerobic Salmonella typhimurium strain YB1 treatment on xenograft tumor in immunocompetent mouse model. Oncol Lett. 2015 Aug; 10(2): 1069–1074.

4、L. Shi, B. Yu, C.H. Cai, W. Huang, B.J. Zheng, D.K. Smith, J.D. Huang. Combined prokaryotic-eukaryotic delivery and expression of therapeutic factors through a primed autocatalytic positive-feedback loop. J Control Release. 2016, 222: 130-40. 

5、L. Shi, B. Yu, C.H. Cai, J.D. Huang. Angiogenic inhibitors delivered by the type III secretion system of tumor-targeting Salmonella typhimurium retards tumor growth. AMB express. 2016; 6 (1): 56. 

6、C.X. Li#, B. Yu#, L. Shi, W. Geng, Q.B. Liu, C.C. Ling, M. Yang, K.T.P. Ng & J. D. Huang & K.Man. ‘Obligate’ anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice. Oncol Lett. 2016 Nov; 13(1): 177-183. 

7、X.L. Tang#, L. Shi#, N. Xie#, Z.J. Liu, M.X. Qian, F. B. Meng, Q.Y. Xu, M.Y. Zhou, X.Y. Cao, W.G. Zhu, B.H. Liu. SIRT7 Antagonizes TGF-β Signaling and Inhibits Breast Cancer Metastasis. Nature Communications. 2017, 8:318

8、L. Shi#, X.L. Tang#, M.X. Qian, Z.J. Liu, F.B. Meng, Q.Y. Xu. Z.M. Wang, L. Fu, B.M. Qin, L. Yang, W.G. Zhu, J. D. Huang. Z.J. Zhou, B.H. Liu. A SIRT1-PRRX1-KLF4 axis regulates cancer stemness and metastasis in breast cancer. Oncogene. 2018, 37: 6299–6315.

9、S.M. Sun, Z. Z.J. Liu, Y. K. Feng, L. Shi, X.Y. Cao, Y. L. Cai, B.H. Liu. Sirt6 deacetylase activity regulates circadian rhythms via Per2. Biochem. Biophys. Res. Commun. 2019, 2: 234-238.

10、X.L. Tang, G. Li, F.T. Su, Y.L. Cai, L. Shi, Z.J. Liu, J. Sun, M. Wang, M. X. Qian, Z. M. Wang, X.Z. Xu, Y.X. Cheng, W.G. Zhu, B.H. Liu. HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration. Nucleic Acids Research. 2020, 48 (6): 2912-2923.

11、M. Wang, L.L. Wang, M.X. Qian, X.L. Tang, Z.J. Liu, Y.W. Lai, Y. Ao, Y.H. huang, Y. Meng, L. Shi, L.Y. Peng, X.Y. Cao, Z. M. Wang, B.M. Qin, B.H. Liu. PML2-mediated thread-like nuclear bodies mark late senescence in Hutchinson-Gilford progeria syndrome. Aging Cell. 2020; 19: e13147.

12、X.C. Tan#, P. Banerjee#, E.A. Pham#, F.U. N. Rutaganira, K. Basu, N. Bota-Rabassedas, H. Fu. Guo, C. L. Grzeskowiak, X. Liu, J. Yu, L. Shi, D. H. Peng, B. L. Rodriguez, J.Q. Zhang, V. Zheng, D.Y. Duose, L. M. Solis, B. Mino, M. G. Raso, C. Behrens, I.I. Wistuba, K. L. Scott, M. Smith, K. Nguyen, G. Lam, I. Choong, A. Mazumdar, J.L. Hill, D.L. Gibbons, P.H. Brown, W.K. Russell, K. Shokat, C.J. Creighton*, J.S. Glenn*, J.M. Kurie*. Golgi-resident PI4P synthesis facilitates metastasis and underlies an actionable secretory vulnerability in chromosome 1q-amplified cancers. Sci. Transl. Med. 2020, 12: 527.

13、G. Q. Chang#, L. Shi#, Y.Q. Ye#, H.L. Shi#, L.X. Zeng, S. Tiwary, J.T. Huse, L. Huo, M. Li, S.C. Zhang, W.J. Zhu, V. Xie, P. Li, L. Han, C. He*, S.Y. Huang*. YTHDF3 induces the translation of m6A-enriched gene transcripts to promote breast cancer brain metastasis. Cancer Cell. 2020, 38 (6): 857-871.

14、X.C. Tan, L. Shi, P. Banerjee, X. Liu, H. Fu. Guo, J. Yu, N. Bota-Rabassedas, L. Rodriguez,  D.L. Gibbons, W.K. Russell, C.J. Creighton, J.M. Kurie. A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.  J Clin. Invest. 2021,131(1): e137186.

Patent achievements 

1、J.D. Huang, L. Shi, and B. Yu, “Therapeutic Delivery and Expression System, Methods and Uses Thereof”, US2015/0064215 A1 (Granted) .

2、J.D. Huang, B. Yu, M. Yang, and L. Shi, “Modified Bacteria and their Uses thereof for the Treatment of Cancer or Tumor”, US009127284 B2 (Granted).

Academic report

1、Development of a Trans-kingdom Expression System in Cancer Therapy. The 22nd Biennial Congress of the European-Association-for-Cancer-Research, 2012/7, S236-S236, Barcelona, Spain, 7-10 July 2012, Poster presentation .

2、Engineered bacteria kill tumors by attacking their microenvironment. InnoCarnival 2015, Hong Kong, China, 31 October 2015.

3、A miR-218-5p-dependent ceRNA network confers resistance to PI4KIIIβ inhibitors. Keystone Symposia Conference 2020, Keystone, US, 26-30 January 2020, Poster presentation. 

4、YTHDF3 induces the translation of m6A-enriched gene transcripts to promote breast cancer brain metastasis. Research “breakthrough” theme at MD Anderson Town Hall, Houston, US, 4 December 2020.

Awards and honors

1、Outstanding Undergraduate Degree Thesis of Beijing University of Chemical Technology, 2006
2、Bronze Medal in International Genetic Engineering Machine Design Competition, 2008
3、Gold Medal in International Genetic Engineering Machine Design Competition, 2007 and 2009

Dr. Lu SongChief scientific officer
Chief laboratory scientist, member of the American Academy of Clinical Laboratory Science. Graduated from the University of Washington School of Medicine and the University of Hong Kong School of Medicine. Chief examiner at the Fred Hutchinson Cancer Research Center-Seattle Cancer Treatment Alliance, and has many years of experience in clinical examination of tumors. license to practice medical examiner in the United States and Hong Kong. The research direction involves tumor pathology, hematology pathology, molecular genetic recombination technology, research and development and application of various tumor detection and screening. More than ten academic papers have been published in international journals such as "International Journal of Molecular Sciences" and "PLoS One" in peer-reviewed SCI journals.

Dr. Lu Song has many years of postdoctoral research experience in biomedical field and overseas study experience. He has obtained the professional qualification of medical laboratory in the United States and Hong Kong. He is familiar with medical diagnosis, neurology and endocrinology, developmental biology and molecular biology. He is proficient in clinical diagnosis technology and biomedical writing in both Chinese and English. He has strong analytical and inductive ability, and has a global view and organization Be flexible, detail oriented and responsible.


❖ Bachelor of Science in Medical Laboratory Science, University of Washington School of Medicine (June 2020)
❖ Postgraduate (Master) Diploma in Molecular and Diagnostic Pathology, Faculty of Medicine, The University of Hong Kong (September 2016)
❖ Doctor of Philosophy in Biochemistry, Faculty of Medicine, The University of Hong Kong (November 2011)
❖ Bachelor of Science in Microbiology and Immunology, McGill University, Canada (November 2006)

Professional certification
❖ Medical examiner ,American Society of Clinical Pathology (ASCP, since August 2020)
❖ Registered Medical Laboratory Technologist, Hong Kong Medical Laboratory Technologist Management Committee (HK Board of MLT, since July 2017)
❖ Chinese Patent Attorney Qualification Certificate (since January 2017)

Working experience

➢ Clinical examiner,Fred Hutchison Cancer Research Institute Center-Seattle Cancer Care Alliance ((January 2021 to present))
Department: Central (comprehensive) laboratory
operating duty:
Processing of blood, cerebrospinal fluid and urine samples; analysis of clinical chemistry results, detection of urine components, immunoassay of cancer factors, blood gas and electrolyte analysis; routine blood test, ESR, artificial classification count of leukocytes and cerebrospinal fluid cells, blood coagulation analysis, distribution of red blood cells and platelets; instrument maintenance and troubleshooting, quality testing, audit results, report critical values.
Main equipment:
Beckman DXC 700au, Beckman access 2, iQ200, Abbott istat1, Sysmex xn-3000, XE-5000, STAGO sta compact Max
➢ Intern Medical Examiner, University of Washington (Seattle) Medical Center (July-November 2020)

Department: Blood pathology laboratory
operating duty:
According to the history of the disease, the antibody test combination was selected; bone marrow, tissue biopsy, coelomic fluid samples were processed; leukocyte count, blood and cell centrifugation smears were performed; immunofluorescence staining of leukocyte surface antigen and intracellular antigen was performed; multi-channel flow cytometry analysis was performed.
Main equipment: flow cytometer BD LSR II

➢ Scientific Director, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University (August 2017-September 2018)

Research project:
Objective To observe the therapeutic effect of pulsed electromagnetic combined with antibiotics on diabetic foot and the effect of leptin on fetal brain development.
operating duty:
To assist postgraduates in experiment and thesis writing; to assist professors in making research plans, analyzing data and applying for research projects; to maintain the daily operation of the central laboratory.

➢ Postdoctoral Researcher, Department of Chemical Pathology, The Chinese University of Hong Kong (January 2015-May 2016)
Research fields: Endocrinology, developmental biology
Research project:
The effects of hyperglycemia during pregnancy on fetal development.
Objective: to optimize the technology of mRNA synthesis in vitro and apply it to primary cell culture and intrapancreatic injection in mice; to analyze and optimize the transgenic mouse model of insulin-dependent diabetes mellitus; to preliminarily conclude the adverse effects of hyperglycemia during pregnancy on early fetal heart and pancreas development by immunofluorescence and image quantitative analysis.

➢ Postdoctoral Researcher, School of Public Health, University of Washington (Seattle) (October 2013-October 2014)

Research fields: neuroscience, animal behavior
Research project:
The function of erk5-mek5 conduction pathway in the development of adult neural stem cells, and the effect of regeneration of adult brain neural stem cells on learning and memory formation in animals.
The induced gene knockin mice model was used to study the regeneration of vascular and neural stem cells. The high expression of erk5-mek5 was confirmed by animal behavior analysis, immunofluorescence and stereology.

➢ Postdoctoral Researcher, Department of Neurology, Department of Internal Medicine, The
Research fields: neuropathology, environmental toxicology
Research project:
The synergistic mechanism of rotenone and LRRK2 on Parkinson's disease;
The results showed that the single gene mutation (LRRK2 R1441G) reduced dopamine resorption capacity of striatum in aged mice and affected motor function; the primary cell culture found that rotenone increased apoptosis of dopamine neurons in mice; the long-term exposure model of rotenone in mutant mice was established;

➢ Postgraduate Diploma, Department of Pathology, The University of Hong Kong (2015-2016)
Research fields: tumor pathology, biostatistics
Project: the application of androgen receptor in the prognosis of estrogen receptor positive breast cancer
Methods and techniques: multivariate model, survival curve analysis.

➢ PhD student, Department of Biochemistry, University of Hong Kong (September 2006-November 2011)

Research fields: biochemistry, molecular biology, developmental biology
Research project:
Coenzyme Q10 plays an important role in the early development of central neurons and inhibits the apoptosis of cerebellar neurons;
Methods and techniques
Molecular cloning, vector construction, primer and probe design, PCR genotyping, qPCR, Southern blot, Western blot, ELISA, antibody purification; primary cell culture, transfection; establishment and conservation of transgenic mouse model, animal behavior analysis; embryonic anatomy, tissue fixation, frozen, paraffin section, histological staining (H & E, Histochemistry, immunohistochemistry, fluorescence, in situ hybridization; confocal fluorescence microscopy, scanning electron microscopy, quantitative image analysis. 

Language and computer

 biomedical English (proficient in thesis writing and literature collation), oral English (fluent), Putonghua

 laboratory information management system (Sunquest)

 proficient in statistical software (SPSS, prism), daily office software (MS Office)

 image processing and stereological quantitative analysis (stereo investigator, Image J, Photoshop)

 biomedical software (anymaze, ethiovision, flow Jo, vector NTI)

Awards and honors

o Member of American Society of Clinical Laboratory Science (ASCLS since 2020)
o American Academy of Clinical Laboratory Sciences-Washington State Student Scholarship (2020)
o Meredith and James Fine Medical Laboratory Technology Scholarship (2020)
o Member of Golden key international honor society (Golden key international honor society, since 2005)
o Canadian National Science and Engineering Research Center Summer Research Scholarship (May-August 2004)

Academic Conference

▪ The 7th International Coenzyme Q10 Association Conference (Seville, Spain, November 2012)
Invited Lecture: The function of PDSS2 (Coenzyme Q10 Synthetase) in the development and functional maintenance of the cerebellum

Publications and Thesis
1、Kwan RL, Lu S, Choi HM, Kloth LC, Cheing GL. 2019. Efficacy of biophysical energies on healing of diabetic skin wounds in cell studies and animal experimental models: a systematic review. International Journal of Molecular Sciences 20(2): 368.
2、Zhang L, Chen X, Sindreu C, Lu S, Storm DR, Zweifel LS, Xia Z. 2019. Dynamics of a hippocampal neuronal ensemble encoding trace fear memory revealed by in vivo Ca2+ imaging. PLoS One 14(7): e0219152. 

3、Lu S, Li J, Lui KO. 2017. Individual variation in conditional β cell ablation mice contributes significant biases in evaluating β cell functional recovery. Frontiers in Endocrinology 8:242. 

4、Lu S, Chow CL, Zhou J, Leung PS, Tsui SK, Lui KO. 2016. Genetic modification of human pancreatic progenitor cells through modified mRNA. Methods in Molecular Biology 1428: 307-317.

5、Wang W, Lu S, Li T, Pan YW, Zou J, Abel GM, Xu L, Storm DR, Xia Z. 2015. Inducible activation of ERK5 MAP kinase enhances adult neurogenesis in the olfactory bulb and improves olfactory function. The Journal of Neuroscience 35:7833-7849. 

6、Zou J, Wang W, Pan YW, Lu S, Xia Z. 2015. Methods to measure olfactory behavior in mice. Current Protocols in Toxicology 63:11 18 11-11 18 21. 

7、Luo J, Chen X, Pan YW, Lu S, Xia Z, Storm DR. 2015. The type 3 adenylyl cyclase is required for the survival and maturation of newly generated granule cells in the olfactory bulb. PLoS One 10(3): e0122057. 

8、Cui J, Li X, Duan Z, Xue W, Wang Z, Lu S, Lin R, Liu M, Zhu G, Huang JD. 2015. Analysis of Kif5b expression during mouse kidney development. PLoS One 10(4): e0126002. 

9、Liu HF, Lu S, Ho PW, Tse HM, Pang SY, Kung MH, Ho JW, Ramsden DB, Zhou ZJ, Ho SL. 2014. LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity. Annals of Clinical and Translational Neurology 1:199-208.

10、Ho PW, Tse ZH, Liu HF, Lu S, Ho JW, Kung MH, Ramsden DB, Ho SL. 2013. Assessment of cellular estrogenic activity based on estrogen receptor-mediated reduction of soluble-form catechol-O-methyltransferase (COMT) expression in an ELISA-based system. PLoS One 8(9): e74065. 

11、Lu S, Lu LY, Liu MF, Yuan QJ, Sham MH, Guan XY, Huang JD. 2012. Cerebellar defects in Pdss2 conditional knockout mice during embryonic development and in adulthood. Neurobiology of Disease 45:219-233. 

12、Gao Y, Niu Y, Wang X, Wei L, Lu S. 2009. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. Journal of Molecular Medicine (Berlin) 87(2):145-152.

Professor Ma BuyongTeam invited Consultant

Professor of medicine, Shanghai Jiaotong University, Frederick National Cancer Research Laboratory, National Cancer Institute, senior scientist. The research field is computational biology, involving the intersection of computational chemistry, synthetic biology, biophysics and pharmacy; Many papers have been published in the fields of synthetic biology and drug design, including microbial evolution, minimum genome design, antibody antigen recognition, drug target ligand recognition and so on. Especially in the study of the dynamic characteristics and biological functions of protein structure and related protein conformation diseases, it is a leading international scholar in this field and direction. Over the years, more than 180 SCI papers have been published (including 8 PNAs, 11 JACS, 2 Angel Chem Int Ed eng, 4 chemical review and 4 nature sub journals). The SCI has been cited for more than 10000 times, with a total of over 500 SCI influencing factors of the first author and the communication author. He has been invited to make academic reports at internationally renowned universities and thematic reports at international academic conferences.

Dr. Jin ChangzhongYB1 Project leader of nano antibody

Doctor of medicine, assistant researcher, State Key Laboratory of infectious disease diagnosis and treatment, Zhejiang University. He has been engaged in postdoctoral research in University of Pittsburgh for 2 years. The main research directions are as follows: (1) the interaction of HIV-1 infection with host factors and innate immune response and its influence on the progression of AIDS( 2) The relationship between non coding RNA and HIV-1 infection( 3) AIDS related laboratory testing technology and clinical application; 4) the development and application of nano antibodies, especially in the field of infectious diseases and tumor diagnosis and treatment. A new generation of nano antibody screening and preparation platform was developed by combining biological mass spectrometry with deep sequencing technology, which greatly improved the preparation efficiency and yield of nano antibody. At present, as the project leader, he has undertaken one National Natural Science Foundation, one doctoral program fund of the Ministry of education, two natural science funds of Zhejiang Province, one public welfare research project of science and Technology Department of Zhejiang Province, and one medical and health science and technology plan of Zhejiang Province. As one of the main researchers, he has successively participated in 6 major scientific and technological projects of the state, such as "prevention and control of major infectious diseases such as AIDS and viral hepatitis". More than 40 SCI papers have been published, 4 national invention patents have been authorized, 1 first prize of Zhejiang medicine and health science and technology award, and 1 second prize of Zhejiang science and technology award.

Dr. Zhou PengYB1 Head of gene programming technology

He holds a PhD in biology from the University of Hong Kong. He was a postdoctoral fellow in Dr Alan Wong's team at the University of Hong Kong. His research focuses on using and optimizing gene editing tools based on CRISPR-Cas9 technology. Develop and optimize the CRISPR Cas9 combination knockout high-throughput screening platform to screen out potential new triple drug combinations for the treatment of ovarian cancer and Parkinson's disease.

Dr. Xie SiYB1 Person in charge of drug design

Doctor of structural biology, School of medicine, University of Hong Kong; Master of bioinformatics and computational biology, University of Leeds, UK. He was a postdoctoral fellow in Dr. Qian Chengmin's team of Li Ka Shing School of medicine, University of Hong Kong. Research direction: To explore the mechanism of DNA damage repair pathway and epigenetic regulation of gene expression through the structural biology research of related proteins. she was awarded the faculty outstanding research output award by Li Ka Shing School of medicine, University of Hong Kong. In 2016, she was selected as the final candidate of HKIS Towngas Young Scientist Award.

Dr. Wang YaoYB1 Director of microenvironment research on tumor metabolism

He graduated from the school of medicine of the University of Hong Kong and is a postdoctoral researcher of the school of medicine of the University of Hong Kong. He has published many articles in cell metabolism (if = 22.4), human reproduction (if = 5.8), circulation research (if = 15.8), fertility & sterlity (if = 6.3) and human behavior and brain. One national invention patent was obtained; He won the young investigator eposter award of the 15th International Symposium on health aging "towards ending youth" of the University of Hong Kong.

Dr. Zheng SongyueYB1 Senior Equipment Development Director

He is a postdoctoral fellow in the Department of chemistry of the University of Hong Kong and a doctor in the Li Ka Shing School of medicine of the University of Hong Kong. He served as the manager of national technical experts in the bioscience Department of China. The main direction of the project is the preparation of molecular and sample products for the whole product development and technology promotion. As a technical expert, it has participated in the project, product design, research and development, production and certification of the COVID-19 extraction reagent locally, helping to realize the landing and listing of the 6 inner month projects. As the main member of the project, he won the annual president award of semefei in 2020.